Navigation Links
Gene Variations Raise the Risk of Childhood Cancer Survivors

Despite surviving the risk of cancer, children were still at the threat of suffering from congestive heart failure due to the complication of the drugs they received during the cancer treatment//.

The researchers studied anthracyclines, a commonly used class of anticancer drugs known to cause heart damage in some patients. The research team investigated two groups of childhood cancer survivors, all of whom had been treated with anthracyclines. The study compared 47 patients with congestive heart failure (CHF) to a control group of 195 patients without CHF.

The researchers investigated 10 polymorphisms, naturally occurring variants in DNA bases called nucleotides, in seven genes they identified as having a role in biological responses to anthracyclines. 'We found that polymorphisms in the GSTP gene significantly increased a patient’s risk for CHF after treatment with anthracyclines,'said Dr. Aplenc. One polymorphism increased risk by five times; another variant was linked to a tripling of risk.

The research group chose particular genes as candidates for study because those genes carry the codes for enzymes involved in metabolizing anthracyclines and the reactive oxygen molecules that anthracyclines produce. If physicians can better classify gene variations that modify side effects of anticancer drugs, they may be able to better tailor treatment plans to individual patients. Thus, knowledge of a patient’s genetic makeup may allow physicians to select a more personalized, less toxic treatment.

'Further study needs to be done, using larger numbers of patients, to determine if these results hold up,' said Dr. Aplenc, a pediatric oncologist at The Children’s Hospital of Philadelphia, 'We hope these findings will provide a scientific foundation for safer, more effective cancer treatments for children.'

Dr. Aplenc’s research abstract was featured in a news conference at the ASCO meeting, which this year has a special focus o n cancer survivors. Dr. Aplenc is an attending oncologist at Children’s Hospital, where he researches gene variations in the enzymes that interact with chemotherapy drugs in children.

(Source: Newswie)
'"/>




Related medicine news :

1. Variations In ingredients From Brand to Brand
2. Genetic Variations In Detoxifying Genes Lead To Lou Gehrigs diseases
3. Food Costs At Hospitals Show Mystifying Variations
4. Stroke Risk Higher with Gene Variations
5. Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk
6. Large Variations in Cost Has No Effect on Length of Stay or Mortality
7. Genetic Variations Associated With Risk of Venous Thrombosis Identified
8. Variations of Post–Heart Attack Depression Affect Recover
9. Heavy Drinking Raises Risk of Liver Cancer
10. Swimming in Chlorinated Pools Raises Asthma Risk
11. New Treatment To Raise Good Cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... NY (PRWEB) , ... February 22, 2017 , ... ... life and athletics. It’s enough to overwork even the sharpest brain. , Power ... offer peak healthy activity without over clocking the brain. Each capsule contains Cognizin® ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... and eligibility requirements effective with the April 2017 testing period. NACCM, a nonprofit ... “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure that newly ...
(Date:2/22/2017)... ... February 22, 2017 , ... A cylindrical ... and sometimes harder to reach ones, according to the results of a clinical ... Conference in Houston by Ricardo A. Hanel, MD, PhD, neurovascular surgeon with Baptist ...
(Date:2/22/2017)... ... February 22, 2017 , ... The ... today, as organizations, advocates, and individuals join together to increase recognition about the ... ultimately save lives. , “Today we mark a nationwide movement to raise awareness ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... MIAMI , February 23, 2017 ML ... stake in Colorado Highlife Tours , a ... strategic plan in partnership with Puration, Inc. (USOTC: PURA) to enter ... luxury cannabis tours product. The Colorado Highlife Tours acquisition announced today ... cannabis tourism strategy. ...
(Date:2/23/2017)... , Feb. 23, 2017 Provectus Biopharmaceuticals, Inc. ... a clinical-stage oncology and dermatology biopharmaceutical company, today announced ... Dominic Rodrigues as special advisers to the ... will advise the board on financial and corporate strategy. ... an investment commitment of up to $2.5 million from ...
(Date:2/23/2017)... NEW YORK , Feb. 22, 2017 /PRNewswire/ ... to the non-hodgkin lymphoma partnering deals and agreements ... Read the full report: http://www.reportlinker.com/p03605669-summary/view-report.html ... and Agreements since 2010 report provides understanding and ... by the world,s leading healthcare companies. ...
Breaking Medicine Technology: